Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) assoc...
Saved in:
Main Author: | Luis Arias |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2010
|
Subjects: | |
Online Access: | https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d17 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability
by: Shibata A, et al.
Published: (2013) -
Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment
by: Kampik A, et al.
Published: (2012) -
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
by: Yamashita M, et al.
Published: (2014) -
Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report
by: Monés J, et al.
Published: (2013) -
Half-dose photodynamic therapy for serous non-neovascular retinal pigment epithelial detachment
by: Inoda S, et al.
Published: (2019)